Navigation Links
Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results
Date:5/8/2009

million, or $0.76 per share, for the nine months ended March 31, 2008.

Cash, cash equivalents and investments were $28.8 million at March 31, 2009. The cash and total investments balance included cash, cash equivalents and short-term investments of $21.6 million and long-term auction-rate securities carried at an estimated value of $7.2 million and classified as long-term investments. Total liabilities, excluding deferred revenue of $14.7 million and a warrant liability of $0.2 million, were $6.4 million at March 31, 2009.

"During the third quarter of fiscal 2009, we wound-down most of our operations and significantly reduced expenses. We also initiated a process to identify and evaluate alternatives for the Company's future. Our board's stated mandate in looking at these strategic alternatives is to maximize the value of our cash and other assets for the benefit of all our shareholders, and to proceed expeditiously in the process," stated William Fletcher, acting Chief Executive Officer.

Assuming accrued costs associated with the Viprinex program are fully paid off by June 30, 2009 as currently estimated, the Company expects to end its fiscal year with approximately $23 million in cash, short-term and long-term investments.

-Tables to follow -

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions. The company recently terminated development of its most advanced product candidate, Viprinex(TM) (ancrod), which was studied in Phase 3 clinical trials as a potential new drug to treat acute ischemic stroke. NTI has more recently chosen not to extend its early-stage research programs for Huntington's and Alzheimer's diseases. NTI has rights to receive payments from an approved drug for Alzheimer's disease and an invest
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
2. Neurobiological Technologies Reports Second Quarter Financial Results
3. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
4. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
5. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
6. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
7. Neurobiological Technologies Reports Going Concern Qualification
8. Steven H. Kane Appointed as President and Chief Executive Officer of Patient Safety Technologies, Inc.
9. Global Med Technologies(R), Inc. to Report First Quarter Financial Results on Friday, May 15, 2009
10. EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results
11. Greenway Medical Technologies PrimeSuite Solution Provides OB/GYN Physicians With Instant Access to Labor and Delivery Information at Point-of-Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... MD (PRWEB) February 28, 2015 The ... present its annual awards at the International Symposium on ... will be held at the Hyatt Regency Bethesda in ... for their dedicated work and commitment to the mission ... the Year Award will be presented to Miriam Ratner. ...
(Date:2/28/2015)... 28, 2015 Dr. Perry Patel ... area residents, recently announced a special offer for the ... treatment option for new and established patients at his Pismo ... a bright, white smile, Dr. Patel and his staff ... marked down from the regular price of $450. , ...
(Date:2/28/2015)... AZ (PRWEB) February 28, 2015 Kaylie ... and alcohol treatment center , and current student obtaining ... University, has implemented a weekly forum in psychoeducation on ... school in Flagstaff, AZ as part of her studies. ... big need for support and counseling at the high ...
(Date:2/28/2015)... ON (PRWEB) February 28, 2015 The ... to announce that they have officially relaunched their website. ... more user-friendly, but it contains a new section about ... access to read the full biographies of each Friedman ... portion of the website was designed to provide our ...
(Date:2/28/2015)... Javon Bea Mercy Health System CEO ... capable by the State of Illinois, enabling potential stroke ... Hospital. , The hospital was required to submit data ... stroke according to national standards of care for stroke ... bypass hospitals not designated as an Emergent Stroke Ready ...
Breaking Medicine News(10 mins):Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2
... shows that fetal cell transplantation for patients with ... of their medications altogether.// ,Parkinson’s disease ... Patients with Parkinson’s lack the chemical dopamine, which ... transplanting aborted human fetal tissue to replace the ...
... to the latest issue of Harvard Heart Letter, testing of ... Clinical testing of eye can predict the condition of the ... ,In a study headed by Dr. John I. Loewenstein, a ... relationship has been drawn between changing conditions of blood vessels ...
... use for cell phones that come complete with cameras: ... phone cameras to send pictures of wounds to specialists ... the wounds from the photos. ,The study involved ... seen in an outpatient clinic. Investigators had a physician ...
... new study shows that infants born under 5.5 pounds ... for developing // type 2 diabetes later in life. ... the only cause of prenatal malnourishment. Abnormal development of ... pressure, which damages vessels can also lead to malnourishment ...
... 100 patients at an ear , nose and throat clinic ... snoring // shouldn't expect to receive a diagnosis of obstructive ... examination alone instead an overnight sleep testing needs to be ... ,For the study, physicians evaluated the patients with a ...
... Dental Society's 140th Midwinter Meeting that begins in US ... over can take a peek to some very innovative ... display there. The convention is also one of the ... ,The showcase of products from 46 countries will ...
Cached Medicine News:
(Date:2/27/2015)... , Feb. 27, 2015  Pomerantz LLP is ... Inc. ("Vitae" or the "Company") (NASDAQ: VTAE ... S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ... and certain of its officers and/or directors have violated ... of 1934.  On February 27, 2015, ...
(Date:2/27/2015)... , Israele, February 27, 2015 ... nel suo sviluppo dell,innovativo sistema di monitoraggio dell,infarto ... primo trial sull,uomo-     ... nello sviluppo di nuovo sistema per il monitoraggio ... (CHF), ha annunciato oggi di aver concluso una ...
(Date:2/27/2015)... 2015 An aggressive campaign to reduce the ... of infection with a dangerous drug-resistant bacteria at The ... difficile, or C.diff, is a bacterium that can cause ... colon. A recent article in the New England Journal ... the United States " asserts that ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3
... approval of amendments, which may ... subpopulations, TOKYO, Japan and INDIANAPOLIS, Oct. 24 ,Daiichi ... Company,(NYSE: LLY ) today announced that enrollment of ... small prasugrel-related,pharmacodynamic clinical trials are being suspended until protocol,amendments ...
... health, we need to fast-track research and approvals,now, says ... the heels,of a study published this month in the ... oral cancer in the New England,Journal of Medicine, the ... the safety of human papillomavirus (HPV),vaccinations for males, and ...
Cached Medicine Technology:Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies 2Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies 3Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies 4The Oral Cancer Foundation Urges HPV Vaccination for Males 2The Oral Cancer Foundation Urges HPV Vaccination for Males 3
Unipolar temporary atrial pacing lead is smaller and thinner than Medtronics standard temporary pacing leads. It is well suited for thin, delicate, atrial tissue....
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: